Conclusion
Despite important advances in the treatment of ALL, HSCT remains the
therapy of choice for patients with failed induction in first remission,
relapsed, and refractory. Administering Blinatumomab prior to HSCT with
the goal of achieving a negative MRD, deep molecular remission provides
a favourable prognosis with better leukemia-free survival rates, overall
survival, and less toxicity. The highlights are that 100% of the
patients went into remission after Blinatumomab infusion and there was
no mortality associated. Our results represent an innovation in Mexico
for pediatric patients with refractory ALL and a background to generate
experience in a medical group.
TABLE 1: Outpatient administration of Blinatumomab Infusion and
Hematopoietic Stem Cell Transplantation as Treatment for Patients with
Refractory Acute Lymphoblastic features. 2015-2020. Hospital Infantil
Teleton Oncologia.